Achieve Life Sciences, Inc. (ACHV) |
|
4.92 0.21 (4.46%)
|
03-24 16:00 |
|
Open: |
4.61 |
Pre. Close: |
4.71 |
|
High:
|
5 |
Low:
|
4.52 |
|
Volume:
|
71,356 |
Market Cap:
|
88(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:23:44 PM |
|
Overall:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
| Target: |
Six months: 6.5  One year: 7.59 |
| Support: |
Support1: 4.71 Support2: 4.17 |
| Resistance: |
Resistance1: 5.57 Resistance2: 6.5 |
| Pivot: |
4.67  |
| Moving Average: |
MA(5): 4.61 MA(20): 4.73
MA(100): 3.7 MA(250): 4.71 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 48.9 %D(3): 36 |
| RSI: |
RSI(14): 54.6 |
| 52-week: |
High: 8.13 Low: 2 |
| Average Vol(K): |
3-Month: 103 (K) 10-Days: 94 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACHV ] has closed below upper band by 31.1%. Bollinger Bands are 13% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.01 - 5.03 |
5.03 - 5.04 |
|
Low:
|
4.47 - 4.49 |
4.49 - 4.52 |
|
Close:
|
4.88 - 4.92 |
4.92 - 4.95 |
|
Company Description |
|
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada. |
Headline News |
Sun, 26 Mar 2023
Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment? - Simply Wall St
Mon, 20 Mar 2023
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q4 2022 Earnings Call Transcript - Yahoo Finance
Wed, 08 Mar 2023
Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation - Yahoo Finance
Fri, 03 Mar 2023
Achieve Life Sciences Announces Presentation of the Phase 3 ... - GlobeNewswire
Mon, 13 Feb 2023
Francis Capital Management Updates Holdings in Achieve Life ... - Nasdaq
Tue, 07 Feb 2023
Achieve Life Sciences Announces Last Subject Dosed in Phase 2 ... - GlobeNewswire
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
18 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
8.4 (%) |
|
% Held by Institutions
|
33.3 (%) |
|
Shares Short
|
574 (K) |
|
Shares Short P.Month
|
600 (K) |
Stock Financials |
|
EPS
|
-3.85 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.1 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-1.28 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
44.72 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2020-07-30 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
